“The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success under Christophe Weber’s remarkable leadership,” said ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...

Takeda Pharmaceutical Company Limited (NYSE ... First of all, we would like to invite our CEO, Christophe Weber to comment. Christophe Weber: Thank you, Chris. Hello, everyone, and thank you ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).

TOKYO, Jan 31, 2025 (BSS/AFP) - Takeda Pharmaceuticals has named Julie Kim as the ... Kim, a US citizen and head of the firm's US business, will next year succeed Christophe Weber who in 2015 became ...

And more. 1. Takeda taps Julie Kim to take over for retiring CEO Christophe Weber Takeda has named Julie Kim, currently the company’s U.S. president, to succeed Christophe Weber as its next CEO ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

We would like to share some important news with you. After years of bringing you the latest insights, analysis and innovation news from the pharma industries, we have made the difficult decision to ...